Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 6, 2017, Pages

  Xu, Jian ^a   Wang, Bin ^a   Hu, Minghao ^a   Huo, Fengmin ^a   Guo, Shaochen ^a   Jing, Wei ^a   Nuermberger, Eric ^b,c   Lu, Yu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bedaquiline; Clofazimine; Mycobacterium tuberculosis; Resistance; Rv0678

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DISTRIBUTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; IN VITRO STUDY; MALE; MIDDLE AGED; MOLECULAR EVOLUTION; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; YOUNG ADULT; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PATHOGENICITY;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85019767316     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00239-17     Document Type: Article

References (29)

1. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado M-G, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2013. Drug resistance beyond XDR-TB: Results from a large individual patient data meta-Analysis. Eur Respir J 42:169 -179. https://doi.org/10.1183/09031936.00136312.
2. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, Twomey D, Winder F. 1957. A new series of phenazines (riminocompounds) with high antituberculosis activity. Nature 179:1013-1015. https://doi.org/10.1038/1791013a0.
3. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. 2012. Clofazimine: current status and future prospects. J Antimicrob Chemother 67:290 -298. https://doi.org/10.1093/jac/dkr444.
4. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. 2013. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: A systematic review and meta-Analysis. J Antimicrob Chemother 68:284 -293. https://doi.org/10.1093/jac/dks389.
5. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, Li M, Li F, Wu M, Zhu Y. 2015. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60:1361-1367. https://doi.org/10.1093/cid/ciu843.
6. Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH. 2015. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A 112:869-874. https://doi.org/10.1073/pnas.1416951112.
7. World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis (2016 update). World Health Organization, Geneva, Switzerland. http://www.who.int/tb/areas-of-work/drug-resistant-Tb/treatment/resources/en.
8. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286:10276 -10287. https://doi.org/10.1074/jbc.M110.200501.
9. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979 -2981. https://doi.org/10.1128/AAC.00037-14.
10. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. https://doi.org/10.1371/journal.pone.0102135.
11. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. 2015. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:2507-2510. https://doi.org/10.1093/jac/dkv150.
12. Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. 2015. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 45:554 -557. https://doi.org/10.1183/09031936.00142914.
13. Torrea G, Coeck N, Desmaretz C, Van De Parre T, Van Poucke T, Lounis N, de Jong BC, Rigouts L. 2015. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 70:2300 -2305. https://doi.org/10.1093/jac/dkv117.
14. Almeida D, Ioerger T, Tyagi S, Li S-Y, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E. 2016. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:4590-4599. https://doi.org/10.1128/AAC.00753-16.
15. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, van Soolingen D. 2010. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:2749 -2753. https://doi.org/10.1128/JCM.00652-10.
16. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54:1022-1028. https://doi.org/10.1128/AAC.01611-09.
17. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. https://doi.org/10.1126/science.1106753.
18. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. 2012. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 56:2326 -2334. https://doi.org/10.1128/AAC.06154-11.
19. Schon T, Jureen P, Chryssanthou E, Giske CG, Sturegard E, Kahlmeter G, Hoffner S, Angeby KA. 2011. Wild-Type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 15:502-509. https://doi.org/10.5588/ijtld.10.0238.
20. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C. 2015. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373:1986 -1988. https://doi.org/10.1056/NEJMc1505196.
21. Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K. 2017. Unexpected high prevalence of resistance-Associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 72:684-690. https://doi.org/10.1093/jac/dkw502.
22. de Knegt GJ, Bruning O, Kate MT, de Jong M, van Belkum A, Endtz HP, Breit TM, Bakker-Woudenberg IA, de Steenwinkel JE. 2013. Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis. Tuberculosis (Edinb) 93:96 -101. https://doi.org/10.1016/j.tube.2012.10.013.
23. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R, Riccardi G. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89:84 -90. https://doi.org/10.1016/j.tube.2008.08.003.
24. Okusu H, Ma D, Nikaido H. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-Antibiotic-resistance (Mar) mutants. J Bacteriol 178:306 -308. https://doi.org/10.1128/jb.178.1.306-308.1996.
25. Nikaido H. 1998. Multiple antibiotic resistance and efflux. Curr Opin Microbiol 1:516 -523. https://doi.org/10.1016/S1369-5274(98)80083-0.
26. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE III, Sherman DR, Parish T, Sacchettini JC. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245. https://doi.org/10.1371/journal.pone.0075245.
27. Phelan J, Coll F, McNerney R, Ascher DB, Pires DE, Furnham N, Coeck N, Hill-Cawthorne GA, Nair MB, Mallard K, Ramsay A, Campino S, Hibberd ML, Pain A, Rigouts L, Clark TG. 2016. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-Tuberculosis drug resistance. BMC Med 14:31. https://doi.org/10.1186/s12916-016-0575-9.
28. Collins L, Franzblau SG. 1997. Microplate alamar blue assay versus BACTEC 460 system for high-Throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004 -1009.
29. Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D, Huang H, Upton AM, Ma Z. 2011. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother 55:5185-5193. https://doi.org/10.1128/AAC.00699-11.